Research progress of metabolomics in children with irritable bowel syndrome
CHEN Xiao-Long, JIANG Mi-Zu.
Department of Gastroenterology and Pediatric Endoscopy Center, Children's Hospital, Zhejiang University School of Medicine/National Clinical Research Center for Child Health/National Children's Regional Medical Center, Hangzhou 310052, China
Abstract:Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by symptoms such as abdominal pain, diarrhea, constipation, and indigestion. Given its unclear etiology and pathogenesis, and the absence of specific biomarkers, clinical diagnosis and treatment of IBS continue to pose significant challenges. In recent years, metabolomics technology, known for its non-invasive, high-throughput, high-precision, and highly reproducible features, has been widely applied in the diagnosis, treatment, and prognosis of various diseases. Therefore, metabolomics technology is expected to offer novel insights and methodologies for the biological mechanism research, diagnosis, and treatment of IBS. This article reviews recent advancements in the application of metabolomics to IBS, exploring its potential value in the clinical diagnosis and treatment of children with this condition.
Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review[J]. Gut, 2017, 66(6): 1075-1082. PMID: 26818616. DOI: 10.1136/gutjnl-2015-311240.
Dunn WB, Broadhurst DI, Atherton HJ, et al. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy[J]. Chem Soc Rev, 2011, 40(1): 387-426. PMID: 20717559. DOI: 10.1039/b906712b.
van Valkengoed IGM, Argmann C, Ghauharali-van der Vlugt K, et al. Ethnic differences in metabolite signatures and type 2 diabetes: a nested case-control analysis among people of South Asian, African and European origin[J]. Nutr Diabetes, 2017, 7(12): 300. PMID: 29259157. PMCID: PMC5865542. DOI: 10.1038/s41387-017-0003-z.
Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome[J]. Clin Gastroenterol Hepatol, 2005, 3(4): 349-357. PMID: 15822040. DOI: 10.1016/s1542-3565(04)00726-8.
Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis[J]. Gut, 2020, 69(1): 74-82. PMID: 30996042. DOI: 10.1136/gutjnl-2018-318160.
Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation[J]. Aliment Pharmacol Ther, 2001, 15(10): 1655-1666. PMID: 11564007. DOI: 10.1046/j.1365-2036.2001.01094.x.
Noorbakhsh H, Yavarmanesh M, Mortazavi SA, et al. Metabolomics analysis revealed metabolic changes in patients with diarrhea-predominant irritable bowel syndrome and metabolic responses to a synbiotic yogurt intervention[J]. Eur J Nutr, 2019, 58(8): 3109-3119. PMID: 30392136. DOI: 10.1007/s00394-018-1855-2.
Keshteli AH, Madsen KL, Mandal R, et al. Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers[J]. Aliment Pharmacol Ther, 2019, 49(6): 723-732. PMID: 30706502. DOI: 10.1111/apt.15141.
Mujagic Z, Tigchelaar EF, Zhernakova A, et al. A novel biomarker panel for irritable bowel syndrome and the application in the general population[J]. Sci Rep, 2016, 6: 26420. PMID: 27263852. PMCID: PMC4893613. DOI: 10.1038/srep26420.
Le Gall G, Noor SO, Ridgway K, et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome[J]. J Proteome Res, 2011, 10(9): 4208-4218. PMID: 21761941. DOI: 10.1021/pr2003598.
Jeffery IB, Das A, O'Herlihy E, et al. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption[J]. Gastroenterology, 2020, 158(4): 1016-1028.e8. PMID: 31843589. DOI: 10.1053/j.gastro.2019.11.301.
Tang SQ, Wang YL, Xie ZY, et al. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome[J]. J Integr Med, 2021, 19(3): 274-281. PMID: 33775600. DOI: 10.1016/j.joim.2021.03.002.
Baranska A, Mujagic Z, Smolinska A, et al. Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach[J]. Aliment Pharmacol Ther, 2016, 44(1): 45-56. PMID: 27136066. DOI: 10.1111/apt.13654.
Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis[J]. Gut, 2022, 71(6): 1117-1126. PMID: 34376515. DOI: 10.1136/gutjnl-2021-325214.
33 Tuck CJ, Abu Omar A, De Palma G, et al. Changes in signalling from faecal neuroactive metabolites following dietary modulation of IBS pain[J]. Gut, 2022. PMID: 36591617. DOI: 10.1136/gutjnl-2022-327260. Epub ahead of print.
Wilson B, Kanno T, Slater R, et al. Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2023, 58(4): 404-416. PMID: 37313992. DOI: 10.1111/apt.17609.
Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome[J]. Gut Microbes, 2016, 7(5): 397-413. PMID: 27662586. PMCID: PMC5046165. DOI: 10.1080/19490976.2016.1215805.
Yamamoto M, Pinto-Sanchez MI, Bercik P, et al. Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients[J]. Metabolomics, 2019, 15(6): 82. PMID: 31111238. DOI: 10.1007/s11306-019-1543-0.